Loading clinical trials...
Loading clinical trials...
Long-term Outcomes of Prostate Cancer Screening Using PSA, Biomarkers and MRI: The STHLM3MRI Trial
This study is an expansion of the screening-by-invitation STHLM3MRI trial for detection of prostate cancer. In summary, we assess longterm outcomes (prostate cancer mortality, incidence and resource use) in men (i) invited and randomized to a screening program using PSA, a biomarker test and MRI; (ii) invited and randomized to a single PSA test with prostate biopsies followed by opportunistic testing and (iii) population controls. Mortality is verified through register data, disease verification is made through in-study biopsy results and registry data.
Age
50 - 74 years
Sex
MALE
Healthy Volunteers
Yes
Karolinska Institutet
Stockholm, Sweden
Start Date
November 1, 2024
Primary Completion Date
October 1, 2025
Completion Date
November 1, 2035
Last Updated
September 4, 2025
7,500
ESTIMATED participants
PSA/Stockholm3/MRI
DIAGNOSTIC_TEST
PSA
DIAGNOSTIC_TEST
Lead Sponsor
Karolinska Institutet
Collaborators
NCT04550494
NCT06842498
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05691465